Circulating Tumor Cells After Neoadjuvant Chemotherapy in Stage I–III Triple-Negative Breast Cancer

被引：0
|
作者：
Carolyn Hall
Mandar Karhade
Barbara Laubacher
Amber Anderson
Henry Kuerer
Sarah DeSynder
Anthony Lucci
机构：
[1] The University of Texas MD Anderson Cancer Center,Department of Surgical Oncology, Unit 444
来源：
Annals of Surgical Oncology | 2015年 / 22卷
关键词：
Overall Survival; Circulate Tumor Cell; Axillary Lymph Node Status; Primary Tumor Size; TNBC Patient;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：552 / 558
页数：6
相关论文
共 50 条
  • [31] The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer
    Abraham, Jean E.
    Pinilla, Karen
    Dayimu, Alimu
    Grybowicz, Louise
    Demiris, Nikolaos
    Harvey, Caron
    Drewett, Lynsey M.
    Lucey, Rebecca
    Fulton, Alexander
    Roberts, Anne N.
    Worley, Joanna R.
    Chhabra, Anita
    Qian, Wendi
    Vallier, Anne-Laure
    Hardy, Richard M.
    Chan, Steve
    Hickish, Tamas
    Tripathi, Devashish
    Venkitaraman, Ramachandran
    Persic, Mojca
    Aslam, Shahzeena
    Glassman, Daniel
    Raj, Sanjay
    Borley, Annabel
    Braybrooke, Jeremy P.
    Sutherland, Stephanie
    Staples, Emma
    Scott, Lucy C.
    Davies, Mark
    Palmer, Cheryl A.
    Moody, Margaret
    Churn, Mark J.
    Newby, Jacqueline C.
    Mukesh, Mukesh B.
    Chakrabarti, Amitabha
    Roylance, Rebecca R.
    Schouten, Philip C.
    Levitt, Nicola C.
    Mcadam, Karen
    Armstrong, Anne C.
    Copson, Ellen R.
    Mcmurtry, Emma
    Tischkowitz, Marc
    Provenzano, Elena
    Earl, Helena M.
    NATURE, 2024, 629 (8014) : 1142 - 1148
  • [32] Efficacy and prognostic factors of neoadjuvant chemotherapy for triple-negative breast cancer
    Feng Ding
    Ru-Yue Chen
    Jun Hou
    Jing Guo
    Tian-Yi Dong
    World Journal of Clinical Cases, 2022, 10 (12) : 3698 - 3708
  • [33] Efficacy and prognostic factors of neoadjuvant chemotherapy for triple-negative breast cancer
    Ding, Feng
    Chen, Ru-Yue
    Hou, Jun
    Guo, Jing
    Dong, Tian-Yi
    WORLD JOURNAL OF CLINICAL CASES, 2022, 10 (12) : 3698 - 3708
  • [34] Residual cancer burden index and tumor-infiltrating lymphocyte subtypes in triple-negative breast cancer after neoadjuvant chemotherapy
    Pinard, Clemence
    Debled, Marc
    Ben Rejeb, Houda
    Velasco, Valerie
    Tunon de Lara, Christine
    Hoppe, Stephanie
    Richard, Elodie
    Brouste, Veronique
    Bonnefoi, Herve
    MacGrogan, Gaetan
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 179 (01) : 11 - 23
  • [35] Residual cancer burden index and tumor-infiltrating lymphocyte subtypes in triple-negative breast cancer after neoadjuvant chemotherapy
    Clémence Pinard
    Marc Debled
    Houda Ben Rejeb
    Valérie Velasco
    Christine Tunon de Lara
    Stéphanie Hoppe
    Elodie Richard
    Véronique Brouste
    Hervé Bonnefoi
    Gaëtan MacGrogan
    Breast Cancer Research and Treatment, 2020, 179 : 11 - 23
  • [36] Monitoring of circulating tumor DNA in metastatic triple-negative breast cancer patients undergoing chemotherapy
    Madic, Jordan
    Kiialainen, Anna
    Bidard, Francois-Clement
    Birzele, Fabian
    Ramey, Guillemette
    Vinolo, Emilie
    Leroy, Quentin
    Rio-Frio, Thomas
    Bernard, Virginia
    Lermine, Alban
    Clausen, Inga
    Giroud, Nicolas
    Schmucki, Roland
    Horn, Carsten
    Spleiss, Olivia
    Lantz, Olivier
    Stern, Marc-Henri
    Pierga, Jean-Yves
    Weisser, Martin
    Lebofsky, Ronald
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [37] Next-generation sequencing of circulating tumor DNA to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy
    Chen, Yu-Hsiang
    Hancock, Bradley A.
    Solzak, Jeffrey P.
    Brinza, Dumitru
    Scafe, Charles
    Miller, Kathy D.
    Radovich, Milan
    NPJ BREAST CANCER, 2017, 3
  • [38] Next-generation sequencing of circulating tumor DNA to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy
    Yu-Hsiang Chen
    Bradley A. Hancock
    Jeffrey P. Solzak
    Dumitru Brinza
    Charles Scafe
    Kathy D. Miller
    Milan Radovich
    npj Breast Cancer, 3
  • [39] Tumor Microenvironment Can Predict Chemotherapy Response of Patients with Triple-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy
    Kim, Dongjin
    Yu, Yeuni
    Jung, Ki Sun
    Kim, Yun Hak
    Kim, Jae-Joon
    CANCER RESEARCH AND TREATMENT, 2024, 56 (01): : 162 - 177
  • [40] Circulating tumor DNA (ctDNA) during and after neoadjuvant chemotherapy and prior to surgery is a powerful prognostic factor in triple-negative breast cancer (TN BC).
    Cavallone, Luca
    Aguilar, Adriana
    Aldamry, Mohammed
    Lafleur, Josiane
    Brousse, Susie
    Lan, Cathy
    Alirezaie, Najmeh
    Bareke, Eric
    Majewski, Jacek
    Pelmus, Manuela
    Ferrario, Cristiano
    Marcus, Elizabeth A.
    Robidoux, Andre
    Discepola, Federico
    Basik, Mark
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345